Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

BACKGROUND: The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+ <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk for AIDS and serious non-AIDS (SNA). We investigated associations of i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Baker, Jason V, Sharma, Shweta, Grund, Birgit, Rupert, Adam, Metcalf, Julia A, Schechter, Mauro, Munderi, Paula, Aho, Inka, Emery, Sean, Babiker, Abdel, Phillips, Andrew, Lundgren, Jens D, Neaton, James D, Lane, H Clifford
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Major Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5751061/
https://ncbi.nlm.nih.gov/pubmed/29308409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx262
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires